A vast search of natural diversity has led scientists at MIT's McGovern Institute and the Broad Institute of MIT and Harvard ...

CAMBRIDGE, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ...

A recent review published in the journal Engineering delves into the significant advancements and potential of CRISPR technologies in the field of ...

A vast search of natural diversity has led scientists at MIT's McGovern Institute and the Broad Institute of MIT and Harvard to uncover ancient ...

During his visit to the Kingdom of Bahrain, the Director-General of the World Health Organization (WHO), Dr. Tedros Adhanom ...

Intellia Therapeutics reported better-than-expected results for the fourth quarter thanks to a boost in its collaboration ...

Intellia Therapeutics (NASDAQ:NTLA) traded higher on Thursday as investors cheered pipeline updates the gene-editing biotech ...

The sickle cell treatments available before Casgevy focused on symptom management such as reducing the frequency of ...

The Nucleic Acid Isolation and Purification Market is projected to be valued at USD 1,178.6 million in 2025 and is expected to grow at a CAGR of 5.6% from 2025 to 2035, reaching USD 2,038.1 million by ...

The strange world of organ preservation is spawning new tech firms. OrganOx has added impetus to the industry with a $142mn ...

Verve offered few details on the early end of a collaboration the companies inked in 2022, saying only that Vertex cited “changing priorities.” ...

Administration officials pressured the NIH to avoid clear advice from the agency’s own lawyers to restart grant funding now.